ArticleAmerican heart journal2014

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Michael A Blazing et al.PubMed ↗Publisher ↗

No numbers read from the abstract.